8-KOther EventsExhibits & Filings

STRYKER CORP 8-K Report, Corporate Update (Jan 19, 2012)

Filed January 19, 2012For Securities:SYK

Summary

Stryker Corporation (SYK) has filed an 8-K report on January 18, 2012, to disclose a significant development concerning its subsidiary, Stryker Biotech. The company announced that Stryker Biotech has reached a settlement with the U.S. Attorney's office for the District of Massachusetts. This event, dated January 17, 2012, marks the resolution of a matter involving the U.S. Attorney's office, the details of which are expected to be found in the furnished press release. While the specific terms and implications of the settlement are not detailed within the 8-K itself, investors should note that such legal settlements can have financial and operational consequences. The accompanying press release (Exhibit 99.1) is incorporated by reference, and investors are encouraged to review it for further information regarding the nature of the settlement and any potential impact on Stryker's business or financial standing.

Key Highlights

  • 1Stryker Corporation announced a settlement between its subsidiary, Stryker Biotech, and the U.S. Attorney's office for the District of Massachusetts.
  • 2The settlement event date was January 17, 2012.
  • 3The disclosure was made via an 8-K filing on January 18, 2012.
  • 4A press release dated January 18, 2012, containing details of the settlement, is furnished as Exhibit 99.1 and incorporated by reference.
  • 5The exhibit and its contents are deemed furnished, not filed, under SEC regulations.

Frequently Asked Questions

The main purpose of this 8-K filing is to inform investors and the public that Stryker Corporation's subsidiary, Stryker Biotech, has reached a settlement with the U.S. Attorney's office for the District of Massachusetts.

More details about the settlement can be found in the press release dated January 18, 2012, which is furnished as Exhibit 99.1 with this 8-K filing and is incorporated by reference.

The 8-K filing itself does not provide details on the financial implications. Investors should refer to the furnished press release (Exhibit 99.1) for information regarding the terms of the settlement, which may include financial penalties, operational changes, or other consequences that could affect Stryker's financial performance.

No, according to the filing, the press release and the information within it are deemed to have been 'furnished' and do not constitute 'filed' information under the Securities Exchange Act of 1934, as amended.